G raft-versus-host disease (GVHD) remains a major obstacle for allogeneic hematopoietic cell transplantation (HCT) (1, 2) . GVHD is considered an exaggerated and undesirable manifestation of an inflammatory response, in which donor lymphocytes encounter foreign Ags in an environment that fosters inflammation (2) . Many reports have showed that the exaggerated immune response in GVHD can be prevented by infusion of donor Foxp3 + regulatory T (Treg) cells (3) (4) (5) (6) (7) (8) (9) . We recently observed that, in a GVHD model of DBA/2 (H-2 d ) donor to MHC-matched but minor Ag-mismatched BALB/c (H-2 d ) recipient, the percentage of donor Treg cells was inversely associated with GVHD severity (9, 10) . Although host APCs were shown to initiate the activation and expansion of pathogenic alloreactive donor T cells (11, 12) , the role of host APCs in donor Treg cell activation and expansion is still largely unknown.
Foxp3 + Treg cells can be divided into natural and adaptive subsets (13) . Natural Treg cells develop and mature in the thymus whereas adaptive Treg cells are converted from conventional Foxp3 2 T cells in the periphery during the T cell activation process under the influence of TGF-b, retinoic acid, and other factors (14-16). Conventional CD4 + T cells can be easily converted into adaptive Treg cells in vitro (17, 18), but in vivo Treg cell conversion appeared to be more difficult (19), although Treg cell conversion can take place in some in vivo circumstances (20) . Additionally, the origin of donor-type Treg cells in allogeneic HCT recipients is still unclear.
IFN-g from alloreactive T cells plays an important role in GVHD pathogenesis (21, 22); however, IFN-g also regulates GVHD by directly inducing apoptosis of the pathogenic T cells and upregulating tissue expression of the costimulatory molecule B7H1 (also known as PD-L1) that could tolerize the activated T cells (23, 24) . B7H1 is constitutively expressed by APCs (i.e., dendritic cells [DCs] ) at a low level but not constitutively expressed by parenchymal cells (25) . IFN-g is identified as a major proinflammatory cytokine in upregulation of B7H1 on APCs and parenchymal cells (24, 26) . B7H1 is shown to bind two receptors, PD-1 and B7.1 (27) . PD-1 is expressed by activated T cells, and extensive studies demonstrate that B7H1/PD-1 interactions result in T cell suppression, anergy, and apoptosis (28). B7.1 is expressed by APCs and activated T cells. Although our recent studies indicate that T cell and APC interaction via B7H1/B7.1 contributes to induction and maintenance of conventional T cell anergy specific to orally administered Ag (29), the impact of B7.1 and B7H1 interaction on Treg cells remains unclear.
The tissue expression of B7H1 was reported to be associated with a high frequency of Treg cells in tumor and autoimmune environments (30). The expression of B7H1 by tumor cells was implicated to augment Treg cell conversion in the tumor microenvironment (31). Expression of low-level B7H1 in normal tissues was also reported to play an important role in Treg conversion in non-disease mice (20) . In light of the findings that IFN-g is the most potent cytokine found so far in the upregulation of B7H1 (25), we hypothesize that IFN-g may augment Treg conversion via upregulation of tissue expression of B7H1. Surprisingly, we found that, in our GVHD model, 1) the Treg cells in the allogeneic HCT recipients were predominantly from the expansion of natural Treg cells, and there were few cells originating from conventional T cells; 2) IFN-g upregulated recipient APC expression of B7H1 and subsequently augmented donor natural Treg cell expansion; and 3) host APC and donor Treg interactions via B7H1/B7.1 play an important role in augmenting the Treg cell expansion.
Materials and Methods

Mice
Wild-type (WT) C57BL/6 (H-2 b ), BALB/c (H-2 d ), and DBA/2 mice were purchased from National Cancer Institute Laboratories (Frederick, MD). Rag2 2/2 BALB/c and Rag2 2/2 C57BL/6 were purchased from Taconic. B7.1 2/2 C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). B7H1
2/2 BALB/c mice were established as previously described (32), and B7H1
2/2
Rag2
2/2 BALB/c were generated through backcrossing B7H1
2/2 to Rag2 2/2 mice. Foxp3gfp/KI DBA/2 mice were generated by backcrossing Foxp3gfp.KI C57BL/6 (33) to WT DBA/2 mice for eight generations. Mice were maintained in a pathogen-free room at the City of Hope Research Animal Facilities (Duarte, CA). All animal protocols were approved by the City of Hope Research Animal Care Committee.
Induction and assessment of GVHD
Bone marrow and spleen cell harvest and donor CD4 + T purification as well as HCT procedures were described in our previous publications (9, 10, 34) . In brief, recipient mice were given 800 rad total body irradiation (TBI) from a [ ) and bone marrow (BM) cells (2.5 3 10 6 ) from DBA/2 donor mice. Thereafter, recipient mice were monitored for clinical GVHD, proteinuria, and survival. The experimental and control groups were set up at the same time and experiments were replicated two to three times. The assessment and scoring of cutaneous clinical GVHD were evaluated based on the area of alopecia as follows: 1, skin ulcers with alopecia ,1 cm 2 in area; 2, skin ulcer with alopecia 1-3 cm 2 ; 3, skin ulcer with alopecia .10% body area; and 4, skin ulcer with alopecia .30% body area.
mAbs and flow cytometric analysis as well as in vivo neutralizing of cytokines
Anti-IFN-g (R4-6A2) was obtained from the American Type Culture Collection and purified from culture supernatant using protein G columns as described in our previous publications (9) . Recipients were i.v. injected with anti-IFN-g or rat IgG (0.5 mg/ml) daily after HCT until they became moribund or developed severe ascites. For anti-PD-1 and anti-B7H1 (43H12) blockade, recipients were neutralized with anti-PD-1, anti-B7H1 (43H12), or hamster IgG (0.5 mg/mice) every day after HCT until they became moribund or developed ascites. Control hamster IgG and rat IgG were obtained from Jackson ImmunoResearch Laboratories (West Grove, PA).
Measurement of autoantibodies and cytokine in serum
Anti-dsDNA IgG was measured with ELISA as previously described (9) . Anti-dsDNA titers are expressed in units per milliliter, using a referencepositive standard of pooled serum from 6-to 7-mo-old NZB/W mice. A 1:100 dilution of this standard serum was arbitrarily assigned a value of 100 U/ml.
Cytokine concentration of IL-6 serum was determined with the DuoSet ELISA development kit (R&D Systems, Minneapolis, MN).
In vivo BrdU labeling
HCT recipients were injected i.p. with BrdU (200 mg/g) twice during a 48-h period, followed by tissue collection and analysis of T cells for BrdU incorporation using BrdU flow kit protocol (BD Pharmingen).
mAbs and flow cytometric analysis
Abs to mouse CD4, CD8, TCR, CD5.1, CD11c, IL-17, IFN-g, PD-1, B7H1, anti-BrdU, and Foxp3 were purchased from BD Biosciences (San Diego, CA) or eBioscience (San Diego, CA). For intracellular staining, cells were stimulated with plate-bound CD3/CD28 for 5 h, and brefeldin A (SigmaAldrich) (10 mg/ml) was added in the last 2 h. Cells were then harvested and stained for cytokines. Dead cells were excluded by a LIVE/DEAD Fixable Aqua Dead Cell Stain kit (Invitrogen, Carlsbad, CA).
Cell isolation from GVHD target organs
Mononuclear cells from liver and skin were processed and collected as previously described (24). Isolation of hepatocytes was performed as previously described (35) .
Real-time PCR
Real-time PCR of Ebi3 and Il12a as well as Bcl-x L were performed as described in our previous publication (36) . We used Ebi3 and Il12a primers described in a recent publication by Collison et al. (37) . The Bcl-x L probe was purchased from SABiosciences (Qiagen).
Statistical analysis
Body weight and survival in different groups were compared using the logrank test (Prism version 5.0; GraphPad Software, San Diego, CA). Comparison of two means was analyzed using an unpaired two-tail Student t test. Comparison of frequencies was analyzed by a x 2 test.
Results
Exacerbation of GVHD by neutralization of IFN-g is associated with marked reduction of natural Treg cells in vivo
We have previously reported that, in an autoimmune-like GVHD model of DBA/2 donor into BALB/c recipient, disease development was associated with high levels of serum anti-dsDNA IgG2a autoantibodies, glomerulonephritis, and proteinurea (9, 10). IFN-g was shown to play a key role in augmenting B cell generation of pathogenic IgG2a autoantibodies (38) . Thus, we tested whether neutralizing IFN-g could ameliorate glomerulonephritis and proteinurea in the GVHD recipients. We observed that anti-IFN-g neutralization reduced serum anti-dsDNA IgG2a by ∼4-fold as compared with the rat IgG control (p , 0.01, Fig. 1A) . Interestingly, the reduction of serum autoantibodies was associated with an accelerated onset of proteinurea. Whereas all (16 of 16) recipients treated with anti-IFN-g developed proteinurea by day 13 after HCT, none of the recipients treated with rat IgG developed proteinurea by this time point (p , 0.01, Fig. 1B) . Additionally, whereas all of the former recipients died of GVHD within 20 d posttransplantation, .50% of the latter survived for .50 d (p , 0.01, Fig. 1C ). Additionally, we compared the histopathologies of the recipients. We observed more severe tissue damage in the kidney, skin, and liver of the recipients treated with the anti-IFN-g as compared with recipients given the rat IgG control (Fig. 1D) , which was consistent with the clinical GVHD exacerbation in recipients treated with anti-IFN-g (Fig. 1B, 1C) . These results indicate that IFN-g neutralization, while reducing autoantibody production, augments GVHD tissue damage in GVHD recipients.
We have reported that the presence of a high percentage of in vivo activated donor-type CD4 + Foxp3 + Treg cells in autoimmune-like GVHD recipients has a profound effect in ameliorating GVHD tissue damage (9) . Thus, we next compared the percentage and yield of the Treg cells in the GVHD recipients treated with anti-IFN-g or rat IgG control. We found that in the recipients treated with anti-IFN-g the percentage and yield of Foxp3 + Treg cells in spleen, liver, and skin was reduced 2-to 4-fold as compared with control recipients given rat IgG (p , 0.01, Fig. 1E, 1F ). Taken together, these results indicate that neutralization of IFN-g results in a marked reduction of donor Treg cells in autoimmune-like GVHD recipients.
Treg cells in GVHD recipients can be either expanded from natural Treg cells or converted from conventional T cells, as described in some autoimmune disease models (13 The Journal of Immunologyrecipient given whole splenocytes was .20-fold higher than that in recipients given GFP 2 splenocytes (Fig. 1G ). Reduction of natural Treg cell expansion in autoimmune-like GVHD recipients by neutralization of IFN-g is associated with downregulation of recipient tissue expression of B7H1
We next sought to determine how IFN-g regulates Treg cell expansion in the autoimmune-like GVHD recipients. Because tissue expression of B7H1 was reported to be associated with a high frequency of Treg cells in tumor environments (30), we tested whether IFN-g promoted Treg cell expansion by augmenting tissue cell expression of B7H1 in the GVHD recipients. Accordingly, 8 d after HCT, when the recipients were still at mixed chimeric stage as indicated by the coexistence of donor-and host-type T cells (Supplemental Fig. 1 ), B7H1 expression on hematopoietic cells (i.e., DCs) and parenchymal cells (i.e., hepatocytes) in chronic GVHD recipients treated with anti-IFN-g or isotype control was analyzed. We observed a significant reduction of B7H1 expression level on both DCs and hepatocytes in recipients treated with anti-IFN-g as compared with control recipients (p , 0.01, Fig. 2A ).
To test the role of B7H1 expressed by donor-and host-type DCs as well as host tissues in donor Treg cell expansion, we next compared Treg cell expansion and GVHD severity in B7H1 2/2 or WT BALB/c recipients. We found that, as compared with WT BALB/c recipients, B7H1 2/2 recipients developed markedly more severe GVHD with accelerated proteinurea, augmented cutaneous tissue damage, and increased mortality (p , 0.01, Fig. 2B-D) .
The augmented clinical signs of GVHD in B7H1 2/2 recipients were associated with elevated tissue damage in GVHD target organs, such as kidney, skin, and liver (Fig. 2E ). Similar to recipients treated with anti-IFN-g, the percentage and yield of Foxp3 + Treg cells in spleen, liver, and skin in B7H1 2/2 recipients were reduced by 2-to 4-fold as compared with that in WT recipients (p , 0.01, Fig. 2F, 2G) . Additionally, the percentage of the converted Treg cells remained very small and was similar in WT and B7H1 2/2 recipients (Supplemental Fig. 2 ). Furthermore, neutralization of IFN-g in B7H1 2/2 recipients did not result in further changes in Treg percentage (Supplemental Fig. 3 ).
We also tested whether host-tissue cell expression of B7H1 affected donor Treg cell suppressor function or their expression of IL-35, because it was recently reported that IL-35 specifically secreted by Treg cells is important not only for mediating Treg cell suppressor function, but also for converting conventional T cells into non-Foxp3-expressing suppressor cells (37, 39 
B7H1/B7.1 but not B7H1/PD-1 interactions promote Treg cell expansion in autoimmune-like GVHD recipients
It has been reported that B7H1 can interact with both PD-1 and B7.1 (27). We next investigated which pathway was required for Treg cell expansion: B7H1/PD-1, B7H1/ B7.1, or both. First, we compared the expression levels of B7.1 and PD-1 on donor CD4 + Treg and T effector (Teff) cells before and after HCT. We found that donor Treg and Teff cells expressed low levels of PD-1 before HCT, and they both upregulated the expression levels after HCT, but there was no significant difference in the expression levels between Treg and Teff cells (Fig. 5A) (Fig. 5C ). These results indicate that Treg cells constitutively express higher level of B7.1 as compared with Teff cells.
Next, we measured the effect of blocking B7H1/PD-1 interactions on donor Treg expansion in the GVHD recipients. Accordingly, BALB/c recipients were treated with control rat IgG or anti-PD-1 blocking Ab, which was previously reported to block the B7H1/PD-1 interactions (40). We found that although anti-PD-1 treatment did not significantly change the percentage of Treg cells in spleen, it increased the percentage of Treg cells in the liver (Fig. 5D ). This is consistent with a previous report showing that blockade of PD-1/PDL1 interaction results in Foxp3 + Treg expansion as judged by the increased percentage of Treg cells among intrahepatic T cells in hepatitis C virus patients (41) . However, we also found that anti-PD-1 treatment not only significantly increased the yield of Treg cells but also increased the yield of Teff cells (p , 0.01, Fig. 5E ). These results indicate that, consistent with the conventional view, B7H1/PD-1 interactions result in the deletion of both Treg and Teff cells. Therefore, expansion of donor Treg cells mediated by host APC expression of B7H1 is unlikely a result from B7H1/PD-1 interaction.
Finally, we explored the role of B7H1/B7.1 pathway in donor Treg cell expansion. Because B7.1 is not only expressed on T cells but also on DCs, direct blockade of B7.1 receptor in vivo cannot specifically test the role of B7H1 interactions with B7.1 on T cells alone. Therefore, we used an anti-murine B7H1 (43H12) that specifically blocks B7H1 interactions with B7.1 without interfering with B7H1 interactions with PD-1 or B7.1 interactions with CTLA4, as described in our recent publication (29). We found that in recipients treated with anti-B7H1 (43H12), the percentage of Treg cells in spleen and liver tissues was reduced 2-to 3-fold as com- pared with control hamster IgG-treated recipients (Fig. 5F ). Additionally, the yield of Treg cells in the spleen was also reduced ∼2-fold in recipients with the blockade of B7H1/B7.1 interactions (p , 0.01), although there was no significant change in the yield of Teff cells (Fig. 5G) . Additionally, administration of anti-B7H1 (43H12) augmented clinical GVHD and increased mortality in recipients (p , 0.01, Fig. 5H, 5I) . Furthermore, blockade of B7H1/B7.1 interactions also reduced donor Treg cell expansion in in vitro culture (p , 0.01, Fig. 5J, 5K ). Taken together, these results indicate that B7H1/B7.1 but not B7H1/PD-1 interactions augment donor Treg cell expansion in autoimmune-like GVHD recipients.
B7.1 is intrinsically critical for Treg cell expansion driven by the inflammatory alloimmune response
To further test the intrinsic role of B7. Fig. 6D ). However, Treg cell expansion was still more dependent on B7.1 
Discussion
We have demonstrated that, in an MHC-matched but minor Agmismatched HCT model of DBA/2 donor to BALB/c recipient, IFN-g augments donor Treg cell expansion via upregulation of host APC expression of B7H1 that interacts with B7.1 expressed on donor Foxp3 + Treg cells. Subsequently, the expansion of Treg cells ameliorates GVHD. Our findings thus reveal a new mechanism by which Treg cells expand and function in inflammatory tissues.
First, we observed that neutralization of IFN-g early after HCT exacerbated clinical GVHD and tissue damage and increased mortality of the recipients, which was associated with a marked reduction of Foxp3 + Treg cells in host lymphoid tissues (i.e., spleen) and GVHD target tissues (i.e., liver and skin). Second, we observed that neutralizing IFN-g in recipients downregulated recipient DC and parenchymal cell expression of B7H1. Exacerbation of GVHD in B7H1 2/2 recipients was also associated with a marked reduction of Treg cells in lymphoid and GVHD target tissues. Third, through the use of bone marrow chimeras, we found that B7H1 expression by recipient hematopoietic cells such as DCs but not parenchymal cells played an important role in donor Treg cell expansion. Fourth, we found that B7H1-mediated signaling augmented donor Treg cell survival rather than proliferation, as the percentage of annexin V + apoptotic cells was increased by 2-fold in B7H1 2/2 recipients, but there was no reduction in the percentage of BrdU + -proliferating Treg cells in B7H1 2/2 recipients. Additionally, the role of IFN-g on Treg cell expansion was not observed in the B7H1 2/2 recipients. Finally, Treg cells from WT or B7H1 2/2 recipients both had strong suppressor function and expressed high levels of IL-35, and no significant difference was observed. All together, our results show that IFN-g plays a pivotal role in the regulation of Treg expansion through B7H1 expression. Although ample evidence supports the idea that interactions of B7H1 with PD-1 on T cells is a major mode in regulating T cell response (25, 42), we observed that augmentation of donor Treg cell survival and expansion occurred via B7H1/B7.1 but not B7H1/PD-1 interactions. We found that blockade of B7H1/PD-1 interactions resulted in an increase rather than decrease of Treg cells in the recipients. In contrast, blockade of B7H1/B7.1 interactions resulted in decrease rather than increase of Treg cells in The Journal of Immunologythe recipients. This in vivo effect of B7H1/B7.1 on expansion of Treg cells was confirmed by in vitro culture assays. Consistent with previous observations that B7.1-mediated signaling on T cells plays an important role on T cell survival (43-45), we found that, although lack of B7.1 signaling led to decreased expansion of both Treg and Teff cells in the alloimmune response, the decrease was more profound with Treg cells. Our results indicate that Treg cells are more dependent on B7.1 signaling for survival, which is probably due to the fact that Treg cells constitutively express higher levels of B7.1 than do Teff cells.
The molecular mechanism by which B7.1 controls the survival and expansion of Treg cells is not yet clear. It has been recently reported that cross-linking B7.1 on CD4 + T cells can activate a calcium-dependent signaling pathway, which leads to increased transcription of T-bet and elevated expression levels of the antiapoptotic molecule, Bcl-x L (44, 45) . We also found that mRNA levels of Bcl-x L in Treg cells isolated from B7H1
2/2 recipients were lower than those in WT controls (Supplemental Fig. 5 ). This may explain why Treg cells have increased apoptosis in B7H1
2/2 recipients. The calcium signaling pathway has been also reported to be a key pathway for Treg cell development and function (46). This is the first evidence that the proinflammatory cytokine IFN-g can elicit downregulation of inflammation through B7H1-mediated Treg cell expansion. Cytokine IFN-g produced by Th1 cells plays an important role in Th1-mediated tissue damage such as in acute and chronic GVHD (2, 21, 22 ). However, IFN-g can also downregulate the Th1 inflammatory response by inducing Th1 cell apoptosis and by upregulating tissue expression of costimulatory molecules such as B7H1 that mediates anergy and apoptosis of activated infiltrating T cells (23, 24, 47, 48) . In contrast, IL-2, another Th1 proinflammatory cytokine, has been shown to downregulate inflammation by augmenting Treg cell survival and expansion (49), as Treg cells express high levels of high-affinity IL-2Ra (CD25). There have been several reports that IFN-g deficiency is associated with a marked reduction of Treg cells in the inflammatory environment (50) (51) (52) . Our study has linked IFN-g, tissue expression of B7H1, and Treg cell expansion together in a concerted pathway. This regulatory loop may be important for modulating the effect of IFN-g on activation of tissue DCs and macrophages, while the IL-2-Treg cell regulatory loop is important for modulating the effect of IL-2 on activation of conventional T cells.
It is of interest that host tissue APC expression of B7H1 predominantly augments Treg cell expansion but not conversion in GVHD recipients. B7H1 expression has been reported to be associated with high-level Treg cell infiltration in autoimmune patient tissues (30). Tumor tissue expression of B7H1 augments Teff cell conversion to Treg cells (31), and the tissue expression of B7H1 plays an important role in the development, maintenance, and function of the induced Treg cells in non-disease mice (20). In contrast, our studies demonstrated that Treg expansion mediated by tissue B7H1 in the GVHD inflammatory environment is predominantly due to natural Treg cell expansion but not conversion. This is consistent with previous observations that there was little Foxp3 + Treg cell conversion in inflammatory autoimmune mice, such as type I diabetes (19). These reports and our studies provide strong evidence that Treg expansion is dominant in inflammatory environments rather than the Foxp3 + Treg cell conversion. This may be due to the fact that inflammatory cytokines such as IL-6 can block Foxp3 + Treg cell conversion. In support of this, we observed that there were high serum levels of IL-6 in recipients given DBA/2 donor spleen cells (Supplemental Fig. 6 ). As IL-35 secreted by natural Treg cells was recently reported to mediate conversion of conventional T cells into non-Foxp3 expression Treg cells in autoimmune and tumor environment (39) , it would be interesting to test whether this is the case in GVHD recipients in future studies.
Note that it is not yet clear how B7H1/B7.1 interaction affects conventional T cell activation in inflammatory environment, although our recent publication indicates that B7H1/B7.1 interaction is required for induction and maintenance of conventional T cell anergy specific to orally administered Ag in a noninflammatory environment (29). This subject is under investigation and is beyond the scope of current report.
In summary, our study has identified a new immune regulatory loop in which T cell-derived cytokine IFN-g can upregulate APC expression of B7H1, and APC interactions with Treg cells via B7H1/B7.1 result in expansion of Treg cells that subsequently downregulate T cell immune response. Additionally, we and others have reported that B7H1/PD-1 interaction mediates conventional T cell anergy and apoptosis and downregulates autoimmunity and GVHD (24, 28, 42). Therefore, therapies that augment tissue expression of B7H1 could be vital for the prevention of inflammatory tissue damage.
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